A Registry Collecting Information From People With T-cell Lymphoma
Collects patient information and optional blood and nail samples for T-cell lymphoma research.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Atlanta, Aurora, Basking Ridge, Boston, Chicago, Columbus, Commack, Duarte, Harrison, Houston, Miami, Middletown, New Haven, New York, Omaha, Philadelphia, Rochester, San Diego, San Francisco, St Louis, Stanford, Tampa, and Uniondale, United StatesSee the 26 sites
- Trial code
- Registry title
- A Registry for People With T-cell Lymphoma
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 27 Jul 2023
- Expected to end
- 27 Jul 2030
- Type of study
- Observational
- Treatments tested
- Optional Blood Sample and Nail Sample
- Record updated
- 20 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a confirmed mature T-cell or NK-cell lymphoma. It builds a database and a collection of tumor samples to study these lymphomas.
- Sex
- All sexes can join.
- Disease stage
- Mature T-cell or NK-cell lymphoma confirmed by tissue testing, of one of the listed types. People with mycosis fungoides need stage IB disease or higher and must be getting treatment.
- Earlier treatment
- People with mycosis fungoides, primary cutaneous anaplastic large cell lymphoma or primary cutaneous acral CD8+ T-cell lymphoma must be getting systemic therapy.
- Biomarker or test result
- Not required, apart from a confirmed diagnosis and a tumor biopsy.
Main reasons for not taking part
- Mycosis fungoides, primary cutaneous anaplastic large cell lymphoma or primary cutaneous acral CD8+ T-cell lymphoma without systemic therapy
- The treating doctor judges that follow-up data or response cannot be collected
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Written informed consent
- Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy
- Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):; T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK cells; Aggressive NK-cell leukemia; Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood; Chronic active EBV infection of T- and NK-cell type, systemic form; Hydroa vacciniforme-like lymphoproliferative disorder; Adult T-cell leukemia/lymphoma; Extranodal NK/T-cell lymphoma, nasal type; Enteropathy-associated T-cell lymphoma; Monomorphic epitheliotropic intestinal T-cell lymphoma; Intestinal T-cell lymphoma, not otherwise specified (NOS); Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract; Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T-cell lymphoma; Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy); Sézary syndrome; Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy); Primary cutaneous Gamma-Delta T-cell lymphoma; Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma; Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy); Peripheral T-cell lymphoma, not otherwise specified; Angioimmunoblastic T-cell lymphoma; Follicular T-cell lymphoma; Nodal peripheral T-cell lymphoma with TFH phenotype; Anaplastic large cell lymphoma, ALK-positive; Anaplastic large cell lymphoma, ALK-negative; Breast-implant associated anaplastic large cell lymphoma
- NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy
Who cannot take part
- Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy
- Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined
Where in United States
- Emory University (Data Collection Only)Atlanta, United StatesContact: Pamela Allen, MD, MScNot yet recruiting
- University of Colorado (Data Collection Only)Aurora, United StatesContact: Bradley Haverkos, MDNot yet recruiting
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge, United StatesContact: Steven Horwitz, MDTaking people
- Dana Farber Cancer Institute (Data Collection Only)Boston, United StatesContact: Eric D Jacobsen, MDNot yet recruiting
- Massachusetts General Hospital (Data Collection Only)Boston, United StatesContact: Salvia Jain, MDNot yet recruiting
- Northwestern Medicine (Data Collection)Chicago, United StatesContact: Jaehyuk Choi, MD, PhDNot yet recruiting
- Ohio State University (Data Collection Only)Columbus, United StatesContact: John Reneau, MD, PhDNot yet recruiting
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)Commack, United StatesContact: Steven Horwitz, MDTaking people
- City of Hope Cancer Center (Data collection only)Duarte, United StatesContact: Jasmine Zain, MDNot yet recruiting
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesContact: Steven Horwitz, MDTaking people
- MD Anderson Cancer Center (Data Collection Only)Houston, United StatesContact: Swami Iyer, MDNot yet recruiting
- University of Miami (Data collection only)Miami, United StatesContact: Jonathan Schatz, MDNot yet recruiting
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United StatesContact: Steven Horwitz, MDTaking people
- Yale University (Data Collection Only)New Haven, United StatesContact: Francine Foss, MDNot yet recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Steven Horwitz, MDTaking people
- Weill Cornell Medical Center (Data Collection Only)New York, United StatesContact: Jia Ruan, MD, PhDNot yet recruiting
- University of Nebraska (Data collection only)Omaha, United StatesContact: Matthew Lunning, DO, FACPNot yet recruiting
- Thomas Jefferson University Hospital (Data Collection Only)Philadelphia, United StatesContact: Pierluigi Porcu, MDNot yet recruiting
- University of Pennsylvania (Data Collection Only)Philadelphia, United StatesContact: Stefan Barta, MD, MS, MRCPCUKNot yet recruiting
- Mayo Clinic (Data Collection Only)Rochester, United StatesContact: Nora Bennani, MDNot yet recruiting
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)San Diego, United StatesContact: Aaron Goodman, MDNot yet recruiting
- University of California San Francisco (Data collection only)San Francisco, United StatesContact: Weiyun Ai, MDNot yet recruiting
- Washington University (Data Collection Only)St Louis, United StatesContact: Neha Mehta-Shah, MD, MSCINot yet recruiting
- Stanford University Medical Center (Data collection only)Stanford, United StatesContact: Michael Khodadoust, MDNot yet recruiting
- Moffitt Cancer Center (Data Collection Only)Tampa, United StatesContact: Lubomir Sokol, MD, PhDNot yet recruiting
- Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United StatesContact: Steven Horwitz, MDTaking people
About the trial
What the trial wants to find out
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
The group in the trial
- Participants with T-Cell Lymphoma
Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma
Treatment: Optional Blood Sample and Nail Sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
- Plain-language title
- A Registry Collecting Information From People With T-cell LymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 May 2026